Germline mutations in the *BRCA1* and the *BRCA2* genes increase the susceptibility for a woman to develop breast and ovarian cancer ([@bib12]; [@bib21]). Women with an inherited mutation in the *BRCA1* or the *BRCA2* gene have a life-time risk of ∼70% of developing breast cancer ([@bib3]; [@bib6]; [@bib1]; [@bib2]; [@bib11]). Reports from the Breast Cancer Linkage Consortium suggested that women with *BRCA1* and *BRCA2* mutations have elevated risk of cancers other than breast and ovarian cancers ([@bib19]; [@bib20]). However, it is not clear to what extent a mutation in *BRCA* genes affects the risk of leukaemia.

Cytotoxic chemotherapy for breast cancer is known to increase the risk of therapy-related myeloid neoplasms ([@bib18]). Chemotherapy-related myeloid neoplasms constitute up to 20% of all acute myeloid leukaemias and myelodysplastic syndromes ([@bib13]). The National Surgical Adjuvant Breast and Bowel Project trials suggest that the use of an intense dose cytotoxic chemotherapy (such as adriamycin and cyclophosphamide), and radiation therapy for breast cancer is associated with a higher incidence of acute myeloid leukaemias, and myelodysplastic syndrome ([@bib17]).

Most women who develop a *BRCA1*- or a *BRCA2*-associated breast cancer are likely to receive chemotherapy and radiation therapy. It is hypothesised that faulty mechanisms, such as altered cellular signalling, enhanced proliferation, diminished apoptosis, and abnormal differentiation increase the risk of chemotherapy-related leukaemias and myelodysplastic syndromes in patients with the *BRCA*-associated breast cancer ([@bib7]). Some case reports have suggested that mutations in *BRCA1* or the *BRCA2* gene might add to the risk of developing leukaemia in patients who receive chemotherapy and radiation therapy for their breast cancer ([@bib8]; [@bib4]). However, there are no prospective data on the subject.

We have previously reported on the incidence of pancreatic cancer, endometrial cancer, and colorectal cancer in *BRCA* mutation carriers ([@bib10]; [@bib16]; [@bib14]). Here we report the incidence of leukaemia in a prospective cohort of *BRCA1* and the *BRCA2* mutation carriers, and also estimate the incidence of leukaemia in women with a *BRCA* mutation who were treated with chemotherapy for breast cancer.

Materials and Methods
=====================

Study cohort
------------

We identified a total of 12 310 women with a *BRCA1* or *BRCA2* mutation through a registry of mutation carriers at the Women\'s College Research Institute, Toronto. The registry collects data from women who have a known pathogenic *BRCA1* or *BRCA2* mutation at 50 different centres in 11 countries in North America and Europe. The study protocol was approved by Ethics Committees/Human Subjects Review Boards of all participating centres. We obtained informed consent from all women before genetic testing. Mutation detection was confirmed by the direct sequencing of DNA.

Women were eligible for study entry if they were 25--74 years of age, and had a mutation in either the *BRCA1* or the *BRCA2* gene. All *BRCA* carrier women had completed a risk assessment questionnaire at study entry and a follow-up questionnaire every 2 years thereafter. The questionnaires collected information on all new cancers diagnosed including site of cancer and age of diagnosis. At some centres, the questionnaires were completed by telephone interview. The eligible women completed at least one follow-up questionnaire. The diagnosis of leukaemia was confirmed by reference to a pathology report or medical record in all cases.

We excluded women who were \<25 years (*n*=454; 3.0%) and \>75 years of age (*n*=107; 0.71%) at baseline, who had no date of birth recorded (*n*=5; 0.03%), who had not completed a follow-up questionnaire (*n*=3,434; 22.9%), who were lost to follow-up (*n*=986; 6.6%), and who had a missing date of death (*n*=81; 0.54), leaving 7243 women who were confirmed carriers eligible for study entry. We followed all women from the date of study entry (baseline) until either: 1) the date of completion of the last follow-up questionnaire, 2) diagnosis of leukaemia, and 3) death from any cause. [Table 1](#tbl1){ref-type="table"} describes characteristics of study cohort.

Incidence and standardised incidence ratios
-------------------------------------------

We estimated the incidence of leukaemia by dividing the total number of new leukaemia cases by the total person-years of follow-up. The incidence was calculated as rate per 100 000 women per year. We calculated the risk of developing leukaemia in the *BRCA1* and the *BRCA2* mutation carriers relative to general population by calculating standardised incidence ratios (SIR). We calculated the SIRs in the following steps. First, we obtained incidence rates of leukaemia for each participating country using GLOBCAN 2012 ([@bib5]). The incidence rates were calculated for each 5-year age bins (\<40, 40--44, 45--49, 50--54, 55--59, 60--64, 65--69, 70--74). Second, we calculated the number of person-years for each age bin in our carrier database. We then calculated the expected number of leukaemia cases for each age bin by multiplying incidence rate of leukaemia with person-years divided by 100 000. The SIRs were calculated as the ratio of observed cancers to expected cancers. The SIRs were calculated according to the type of *BRCA* mutation (*BRCA1*, *BRCA2*, combined), country of residence (Canada, Italy, Poland, and the United States), age groups (\<50 years, ⩾50 years), breast cancer status (yes/no), and chemotherapy (yes/no) for breast cancer.

Results
=======

After a mean follow-up time of 6.1 years (range 1.0--19.5 years), five women (two *BRCA1*, three *BRCA2*) were diagnosed with leukaemia. [Table 2](#tbl2){ref-type="table"} presents characteristics of incident cases of leukaemia. Three women (one *BRCA1*, two *BRCA2*) were diagnosed with acute myeloid leukaemia and one woman (*BRCA2*) developed chronic lymphocytic leukaemia; one women (*BRCA1*) developed acute leukaemia but the subtype of leukaemia could not be determined. The mean age at diagnosis of leukaemia was 53.4 years. The mean age was 43 years for *BRCA1* mutation carriers and was 60.3 years for *BRCA2* mutation carriers.

All five leukaemia patients had previous history of breast cancer. The mean age at the diagnosis of breast cancer was 43.2 years (*BRCA1*=34.5 years, *BRCA2*=49.0 years). Four women (one *BRCA1*, three *BRCA2*) received chemotherapy for their breast cancer. The *BRCA1* mutation carrier who received chemotherapy for breast cancer developed acute myeloid leukaemia 3 years after initial treatment for breast cancer. Of three *BRCA2* mutation carriers, two developed acute myeloid leukaemia after 18 and 10 years, and one patient developed chronic lymphocytic leukaemia 6 years after the treatment for breast cancer.

Overall, five cases of leukaemia were observed *vs* 4.3 cases expected (SIR=1.16, 95% CI: 0.43--2.58, *P*=0.69). Among the entire cohort, the incidence of leukaemia was 11.3 per 100 000 women per year. Two incident leukaemia cases were observed among the *BRCA1* carriers *vs* 3.02 cases expected (SIR=0.66, 95% CI: 0.11--2.19, *P*= 0.61) ([Table 3](#tbl3){ref-type="table"}). For *BRCA2* carriers, three leukaemia cases were observed *vs* 1.24 cases expected (SIR=2.42, 95% CI: 0.61--6.58, *P*=0.17). Among *BRCA2* mutation carriers the incidence rate of leukaemia was 27.1 per 100 000 women per year. Compared to the general population, the risk of leukaemia was higher for women \<50 years (SIR=2.30, 95% CI: 0.38--7.59, *P*=0.27); the risk was lower for women 50 years and above (SIR=0.87, 95% CI: 0.22--2.38, *P*=0.88). However, the absolute difference in the annual risk of leukaemia was statistically not significant between the two age groups (*P*=0.77).

Compared to general population, the risk of leukaemia was five-fold higher for women who had a prior *BRCA2*-associated breast cancer (SIR=4.76, 95% CI: 1.21--12.96, *P*=0.03), but was not significantly higher for women with *BRCA1*-associated breast cancer ([Table 4](#tbl4){ref-type="table"}). Among all women with *BRCA*-associated breast cancer who received chemotherapy, four cases of leukaemia were observed *vs* 1.4 cases expected (SIR=2.86, 95% CI: 0.91--6.89, *P*=0.07). Among women who did not receive chemotherapy, one case of leukaemia was observed *vs* 0.83 cases expected (SIR=1.20, 95% CI: 0.06--5.94, *P*=0.76) ([Table 4](#tbl4){ref-type="table"}).

The risk of leukaemia was eight-fold higher for women who received chemotherapy for a *BRCA2*-associated breast cancer (SIR=8.11, 95% CI: 2.06--22.07, *P*=0.007) ([Table 5](#tbl5){ref-type="table"}). For *BRCA1* mutation carriers who received chemotherapy for breast cancer, the risk of leukaemia was similar to the risk in the general population (SIR=0.97, 95% CI: 0.05--4.79, *P*=1.01). The absolute risk of leukaemia for women who received chemotherapy for breast cancer was 0.06% (1 of 1776 women) for the *BRCA1* carriers and was 0.55% (3 of 540 women) for the *BRCA2* carriers.

Discussion
==========

Women who carry a mutation in *BRCA* genes are concerned about their risk of developing cancers other than breast and ovarian cancers. In this prospective study of the *BRCA* mutation carriers, we observed a two-fold increase in the risk of leukaemia among carriers of a *BRCA2* mutation, compared to the risk in general population. The increased risk of leukaemia was statistically significant if a *BRCA2* mutation carrier had breast cancer (SIR=4.69, *P*=0.03), and had received chemotherapy (SIR=8.11, *P*=0.007).

The risk of leukaemia in the *BRCA1* and the *BRCA2* mutation carriers was first reported in the earlier studies of the Breast Cancer Linkage Consortium ([@bib19]; [@bib20]). In their first study, the Breast Cancer Linkage Consortium estimated the risk of leukaemia among the probable carriers of a *BRCA2* mutation, relative to non-carriers, and subjects with an unknown mutation status ([@bib19]). The relative risk of leukaemia in probable carriers of the *BRCA2* mutation was 1.12 (95% CI: 0.30--4.25). The risk of leukaemia was relatively lower in the *BRCA1* mutation carriers, compared to non-carriers and untested women (relative risk=0.88, 95% CI: 0.37--2.14) ([@bib20]). Relative risks reported in studies of the Breast Cancer Linkage Consortium were based on the review of family histories, and diagnosis of leukaemia was based on the information provided by a family member. In comparison, our estimates are based on a prospective follow-up of women with a known *BRCA* mutation status.

Two case reports suggest that carriers of a *BRCA2* mutation who receive treatment for breast cancer might be at a higher risk of developing haematologic malignancies, in particular, leukaemias ([@bib7]; [@bib4]). Fruscalzo *et al* ([@bib8]) reported of a patient who developed chronic lymphocytic leukaemia 2 years after receiving chemotherapy for the *BRCA2*-associated breast cancer. In another case-series, Cole and Strair ([@bib4]) reported on six patients who developed either acute myelogenous leukaemia or myelodysplasia after receiving treatment for breast cancer. Three of six (50%) patients in this case-series had a mutation of one of the *BRCA* genes (*BRCA1* or *BRCA2*), and all of them received adriamycin and cyclophosphamide-based chemotherapy for their breast cancer. Hall *et al* ([@bib9]) reported acute myelogenous leukaemia in three Hispanic *BRCA2* carriers who did not receive chemotherapy or radiation therapy for early-stage breast cancers.

The actual risk of leukaemia in our *BRCA* cohort was \<1%. One potential reason why the impact of *BRCA* mutations on leukaemia incidence might be less than that for breast and ovarian cancer susceptibility could be that the self-renewal potential of leukaemic cells is dependent on genome stability, which is compromised when there is a *BRCA* mutation ([@bib15]).

Our results are based on the prospective follow-up of the largest cohort of women who are confirmed carriers of a *BRCA* mutation, and with two-yearly follow-up of all women.

Our results should be interpreted with caution. Our *BRCA* cohort included only women and therefore we cannot estimate the incidence of leukaemia in male carriers of a *BRCA* mutation. Moreover, the number of incidence cases was relatively small in our study which limits the precision of risk estimates for subgroups. Furthermore, missing follow-up information for nearly 30% women could potentially bias our estimates.

In conclusion, our findings suggest that women with a *BRCA2*-associated breast cancer might be at a higher risk of developing leukaemia; in particular if these women receive chemotherapy for breast cancer. However, given a very low actual risk, we suggest that the risk of leukaemia in the *BRCA* mutation carriers should not influence the choice of chemotherapy to treat their breast cancer.
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###### Baseline characteristics of study cohort

  **Characteristic**                            **All women** ***N*****=7243**   ***BRCA1*** ***N*****=5397**   ***BRCA2*** ***N*****=1790**   **Other**[a](#t1-fn1){ref-type="fn"} ***N*****=56**
  --------------------------------------------- -------------------------------- ------------------------------ ------------------------------ -----------------------------------------------------
  **Age, years**                                                                                                                               
  Mean (min, max)                               47.0 (25--74.9)                  46.2 (25--74.9)                49.4 (25--74.9)                48.3 (28--73)
  **Breast cancer**                                                                                                                            
  Yes                                           3200                             2353                           813                            34
  No                                            4040                             3042                           976                            22
  Not known                                     3                                2                              1                              0
  **Chemotherapy**[b](#t1-fn2){ref-type="fn"}                                                                                                  
  Yes                                           2346                             1776                           540                            30
  No                                            788                              544                            241                            3
  Not known                                     66                               33                             32                             1
  **Country**                                                                                                                                  
  Canada                                        2255                             1229                           994                            32
  Italy                                         103                              84                             19                             0
  USA                                           2185                             1414                           749                            22
  Poland                                        2700                             2670                           28                             2

Other category includes women who were confirmed carriers of either *BRCA* mutation, but the type of *BRACA* mutation (*BRCA1* or *BRCA2*) was not known.

Analysis is restricted to women who developed breast cancer (*n*=3200).

###### Characteristics of incidence cases of leukaemia in *BRCA* carriers

  **Case no.**   **Age at breast cancer diagnosis**   **Treatment of breast cancer**                       **Age at leukaemia diagnosis**   **Subtype of leukaemia**                     ***BRCA*** **mutation**   **Mutation description**   **Status**   **Country**
  -------------- ------------------------------------ ---------------------------------------------------- -------------------------------- -------------------------------------------- ------------------------- -------------------------- ------------ -------------
  1              35                                   No treatment                                         49                               Acute leukaemia[a](#t2-fn2){ref-type="fn"}   *BRCA1*                   Exon 11 3913delA           Dead         Italy
  2              34                                   Surgery Chemotherapy                                 37                               Acute myeloid leukaemia (M3)                 *BRCA1*                   Exon 12 Q1395X             Alive        Canada
  3              52                                   Surgery Chemotherapy Tamoxifen                       70                               Acute myeloid leukaemia                      *BRCA2*                   Exon 11 6024delTA          Dead         Italy
  4              50                                   Surgery Chemotherapy Radiation Tamoxifen Letrozole   60                               Acute myeloid leukaemia                      *BRCA2*                   Exon 11 3772delTT          Alive        Canada
  5              45                                   Surgery Chemotherapy Tamoxifen                       51                               Chronic lymphocytic leukaemia                *BRCA2*                   IVS24--18C\>A              Alive        USA

Acute myeloid leukaemia, M3 is the acute promyelocytic leukaemia.

The subtype of acute leukaemia is not known for this patient.

###### Observed and expected number of leukaemia cases in *BRCA1* and *BRCA2* carriers according to country of origin

  **Country**     ***BRCA*** **status**   ***N***   **Person-years**   **Observed cancers**   **Expected cancers**   **Incidence (per 100 000 women)**    **SIR (95% CI)**    ***P*****-value**
  -------------- ----------------------- --------- ------------------ ---------------------- ---------------------- ----------------------------------- -------------------- -------------------
  All combined             All             7243         44255.18                5                     4.3                          11.3                  1.16 (0.43--2.58)          0.69
                         *BRCA1*           5397         32864.14                2                     3.02                          6.1                  0.66 (0.11--2.19)          0.61
                         *BRCA2*           1790         11074.09                3                     1.24                         27.1                  2.42 (0.61--6.58)          0.17
  Canada                   All             2255         16431.59                2                     2.02                         12.2                  0.99 (0.17--3.27)          0.98
                         *BRCA1*           1229         9211.06                 1                     1.05                         10.8                  0.95 (0.02--5.31)          0.56
                         *BRCA2*            994         7010.24                 1                     0.95                         14.3                  1.05 (0.05--5.19)          0.86
  Italy                    All              103          463.32                 2                     0.04                         431.7                  50 (8.38--165.2)         0.0007
                         *BRCA1*            84           348.18                 1                     0.03                         287.2                 33.3 (1.67--164.4)         0.03
                         *BRCA2*            19           115.14                 1                     0.01                         868.5                  100 (5.0--493.2)          0.01
  USA                      All             2185         12343.86                1                     1.30                          8.1                  0.77 (0.04--3.79)           0.9
                         *BRCA1*           1414         8379.13                 0                     0.87                           0                          ---                  ---
                         *BRCA2*            749         3862.16                 1                     0.43                         25.9                  2.33 (0.12--11.47)         0.42
  Poland                   All             2700         15016.41                0                     0.84                          ---                         ---                  ---
                         *BRCA1*           2670         14925.77                0                     0.84                          ---                         ---                  ---
                         *BRCA2*            28           86.56                  0                    0.006                          ---                         ---                  ---

Abbreviations: CI, confidence interval; SIR, standardised incidence ratio.

###### Observed and expected number of leukaemia in *BRCA* carriers according breast cancer status

  ***BRCA*** **status**    **Breast cancer**   ***N***   **Person-years**   **Observed cancers**   **Expected cancers**   **Incidence rate per 100 000 per year**     **SIR 95% CI**     ***P*****-value**
  ----------------------- ------------------- --------- ------------------ ---------------------- ---------------------- ----------------------------------------- -------------------- -------------------
  All                             No            4040         24628.12                0                     2.03                             ---                            ---                  ---
                                  Yes           3200         19617.74                5                     2.26                            25.5                     2.21 (0.81--4.90)          0.11
  *BRCA1*                         No            3042         18483.11                0                     1.42                             ---                            ---                  ---
                                  Yes           2353         14376.04                2                     1.60                            13.9                     1.25 (0.21--4.13)          0.69
  *BRCA2*                         No             976         6027.48                 0                     0.60                             ---                            ---                  ---
                                  Yes            813         5042.28                 3                     0.64                            59.5                     4.69 (1.19--12.76)         0.03

Abbreviations: CI, confidence interval; SIR, standardised incidence ratio.

###### Observed and expected number of leukaemia in *BRCA-associated* breast cancer patients according to chemotherapy

  ***BRCA*** **status**    **Chemotherapy**   ***N***   **Person-years**   **Observed cancers**   **Expected cancers**   **Incidence rate per 100 000 per year**     **SIR 95% CI**     ***P*****-value**
  ----------------------- ------------------ --------- ------------------ ---------------------- ---------------------- ----------------------------------------- -------------------- -------------------
  All                             No            788         5257.98                 1                     0.83                            19.0                     1.20 (0.06--5.94)          0.76
                                 Yes           2,346        14107.09                4                     1.40                            28.3                     2.86 (0.91--6.89)          0.07
  *BRCA1*                         No            544         3582.22                 1                     0.56                            27.9                     1.79 (0.09--8.81)          0.54
                                 Yes           1,776        10674.21                1                     1.03                             9.4                     0.97 (0.02--5.41)          0.55
  *BRCA2*                         No            241         1662.88                 0                     0.27                             ---                            ---                  ---
                                 Yes            540         3350.50                 3                     0.37                            89.5                     8.11 (2.06--22.07)         0.007

Abbreviations: CI, confidence interval; SIR, standardised incidence ratio.
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